American Journal of Biology and Natural Sciences
https://biojournals.us/index.php/AJBNS
ISSN: 2997-7185

Bioactive Compounds Isolated and Characterized from Ocimum Sanctum Leaves in Antidiabetic

Ms. Shubhee Yadav
M.Pharm Student, Institute of Pharmaceutical Sciences & Research, Unnao

Dr. Sangeeta Singh
Associate Professor, Institute of Pharmaceutical Sciences & Research, Unnao

Received: 2025, 15, Oct
Accepted: 2025, 21, Nov
Published: 2025, 13, Dec

Annotation: Diabetes mellitus is a significant global health concern, driving the search for effective natural therapeutic agents with fewer side effects than conventional drugs. Ocimum sanctum L., commonly known as Holy Basil or Tulsi, has shown promising antidiabetic properties in traditional medicine and scientific studies. This research focuses on the bioactivity-guided isolation and characterization of the specific compounds within O. sanctum leaves responsible for its blood glucose-lowering effects.

The methodology typically involves extracting the active components using solvents such as hydroalcohol or ethanol and then fractionating the crude extract via column chromatography. The resulting fractions are subjected to rigorous screening for antidiabetic activity, often in alloxan or streptozotocin-induced diabetic rat models. Active fractions are analyzed using advanced spectroscopic techniques, including Ultraviolet (UV), Infrared (IR), Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR) spectroscopy, to determine the precise chemical structures of the bioactive compounds.

Key findings from various studies reveal that *O. sanctum* contains several classes of antidiabetic phytochemicals, including phenols, flavonoids, and terpenoids. One particularly potent compound isolated through this process was identified as a **tetracyclic triterpenoid** [16-hydroxy-4,4,10,13-tetramethyl-17-(4-methyl-pentyl)-hexadecahydro-cyclopenta[a]phenanthren-3-one]. Other important constituents contributing to the antidiabetic effect include eugenol, ursolic acid, orientin, and vicenin. These compounds work through multiple mechanisms, such as stimulating pancreatic insulin secretion, enhancing glucose utilization by tissues, and inhibiting enzymes like alpha-amylase, while also providing crucial antioxidant and anti-inflammatory protection to pancreatic beta-cells.

In conclusion, the isolated bioactive compounds, particularly the tetracyclic triterpenoid, demonstrate significant antidiabetic potential, supporting the traditional use of *O. sanctum* and offering promising avenues for the development of new, effective, and safer treatments for diabetes and its associated complications.



Fig-1 Compound Chart

Intorduction:-

1. Background and Significance

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia, which results from defects in insulin secretion, action, or both. The global prevalence of diabetes is a significant public health concern, with projections indicating a continued increase in patient numbers worldwide. While conventional treatments, including insulin injections and oral hypoglycemic agents like glibenclamide, are available, they often come with limitations and side effects such as hypoglycemia, weight gain, and skin diseases. This has led to a growing interest in exploring natural products with antidiabetic potential, which are often perceived as safer and more cost-effective alternatives.

Ocimum sanctum Linn., widely recognized as Holy Basil or Tulsi, is an aromatic herb belonging to the Lamiaceae family with deep roots in Ayurvedic and Siddha systems of traditional medicine in India and Southeast Asia. Traditionally referred to as the "elixir of life," different parts of the plant, especially the leaves, are used to manage various ailments, including stress, inflammation, and notably, diabetes ("madhumeha"). Scientific evidence from both in vitro and in vivo studies has increasingly supported these traditional claims, demonstrating the plant's significant hypoglycemic, antioxidant, and antidyslipidemic effects in various animal models.

The therapeutic efficacy of *O. sanctum* is attributed to its complex phytochemical composition, which includes volatile oils (primarily eugenol, methyl eugenol), flavonoids (orientin, vicenin, apigenin, cirsimaritin), and triterpenoids (ursolic acid). These compounds exhibit a wide range of pharmacological properties that are highly beneficial in managing diabetes and its complications, particularly oxidative stress.

However, the synergistic interactions between these numerous bioactive constituents often limit a complete understanding of their individual therapeutic effectiveness. Therefore, this area of research focuses specifically on the **bioactivity-guided isolation and characterization** of the individual compounds responsible for the most potent antidiabetic effects. By employing systematic approaches such as solvent extraction, chromatography, and advanced spectroscopic analysis (UV, IR, MS, NMR), researchers aim to identify the precise chemical structures and elucidate the specific mechanisms of action of these active ingredients. This research is crucial for validating the plant's traditional use and potentially developing novel, standardized, and effective single-compound antidiabetic agents for future therapeutic applications

Structure and Botanical classification of plant Profile

Ocimum sanctum, commonly known as **Tulsi** or **Holy Basil**, is an aromatic, many-branched perennial subshrub native to the Indian subcontinent, highly valued in traditional medicine and Hindu culture.

Plant Structure (Morphology)

- **Habit and Size:** It is an erect, herbaceous, much-branched plant, typically growing to a height of 30–75 cm (about 1 to 2.5 feet).
- **Stem:** The stems are quadrangular (four-angled), often hairy, and slightly woody at the base.
- **Leaves:** Leaves are simple, opposite, and decussate (arranged in a cross-like pattern). They are ovate to elliptic-oblong, up to 5 cm long, with entire or slightly toothed (serrate) margins. They are minutely dotted with glands, covered in soft hairs (pubescent), and have a strong, characteristic aroma. Two common varieties exist: the green-leaved 'Rama Tulsi' and the purplish-leaved 'Krishna Tulsi'.
- **Flowers:** Small, purplish or crimson flowers are borne in elongated terminal racemes (spikes) arranged in close whorls.
- **Fruit and Seeds:** The fruit is a dry schizocarp, which splits into four small, subglobose or ellipsoid nutlets. The seeds are pale brown or reddish with small black markings.
- **Root:** The plant possesses a taproot system.

Botanical Classification

Ocimum sanctum is classified within the large and aromatic mint family, Lamiaceae.

Taxonomical Rank	Classification
Kingdom	Plantae
Division/Phylum	Magnoliophyta (Tracheophytes)
Class	Magnoliopsida (Angiosperms, Eudicots, Asterids)
Order	Lamiales
Family	Lamiaceae (formerly Labiatae)
Genus	*Ocimum*
Species	*O. sanctum* (also known as *Ocimum tenuiflorum*)

The binomial name is ***Ocimum sanctum*** L. or ***Ocimum tenuiflorum*** L., with *O. tenuiflorum* being the currently accepted name.

Research involving the antidiabetic properties of ***Ocimum sanctum*** envisages several future directions, primarily focusing on advanced characterization, clinical validation, nanoformulation development, and mechanistic studies to develop safe and effective therapeutic agents.

Research envisaged

- **Isolation and Characterization of Novel Compounds:** While compounds like eugenol and ursolic acid have been studied, further research is needed to isolate and characterize other novel or lesser-known phytochemicals responsible for the plant's full spectrum of antidiabetic activity. Advanced techniques like metabolomics and proteomics can help identify these potential active agents and understand their pathways.
- **Elucidating Mechanisms of Action:** A significant area of future study is the precise elucidation of the molecular mechanisms through which *O. sanctum* extracts and its isolated compounds exert antidiabetic effects. This includes investigating their interaction with specific biological targets (e.g., PPAR-γ activation, DPP-IV inhibition, glucose transporter activity) using in silico, in vitro, and in vivo models.
- **Clinical Efficacy and Safety Studies:** Most studies to date have been preclinical (animal models or in vitro). Well-designed, systematic human clinical trials are "envisaged" to confirm the safety, optimal dosage, dose form, and clinical efficacy of *O. sanctum* preparations in managing type 2 diabetes and related metabolic disorders in human populations.
- **Standardization and Quality Control:** Research needs to focus on establishing standardized protocols for cultivation, harvesting, and extraction, as the proportion of bioactive compounds can vary considerably depending on these factors. This will ensure consistent quality and reproducible therapeutic outcomes for pharmaceutical preparations.
- **Nanotechnology Applications:** The development of novel formulations using nanotechnology (e.g., green-synthesized nanoparticles) is a promising area of envisaged research. Nanoformulations could enhance the bioavailability, sustained release, and targeted delivery of the active antidiabetic compounds, potentially increasing efficacy and reducing side effects.
- **Synergistic Potential in Polyherbal Formulations:** Investigating the synergistic effects of *O. sanctum* with other antidiabetic medicinal plants or conventional drugs (like metformin) could lead to more effective polyherbal or integrative therapies.
- **Toxicological Assessment:** While generally considered safe for traditional use, comprehensive toxicological assessments of isolated bioactive compounds are necessary to meet modern regulatory standards for novel drug development.

2. Research Gap and Rationale

Despite extensive traditional use and promising scientific evidence for the antidiabetic potential of *Ocimum sanctum*, several research gaps need to be addressed to facilitate its transition into a standardized, modern pharmaceutical agent.

Research Gaps

- **Standardization of Dosage and Preparation:** While various studies confirm the efficacy of crude extracts (aqueous, ethanolic, etc.), there is a lack of consensus on the most effective and safe dosage for human consumption. Traditional medicine often lacks standardized preparations, and safe dosages of specific extracts are missing from some reviews.
- **Clear Mechanisms of Action for Specific Compounds:** Many studies have identified a range of compounds (eugenol, ursolic acid, flavonoids) and suggested multiple mechanisms (insulin secretion, enzyme inhibition, antioxidant effects). However, comprehensive research linking specific isolated compounds to precise molecular pathways *in vivo* is limited. For example, some extracts inhibit alpha-amylase but not alpha-glucosidase, highlighting the need to understand which specific compounds are responsible for each effect.
- **Clinical Efficacy and Safety in Humans:** Most existing research has been conducted using *in vitro* assays or animal models (mice, rats, rabbits). There is a significant gap in robust clinical trials that verify the efficacy and long-term safety of isolated *O. sanctum* compounds in human subjects.
- **Comparative Efficacy with Standard Drugs:** While some studies show effects comparable to standard drugs like glibenclamide, the comparative efficacy of isolated, pure *O. sanctum* compounds versus existing synthetic drugs needs more rigorous investigation.

Key Findings from Literature Review

Efficacy:

- **Blood Glucose Reduction:** Multiple studies in diabetic rats and mice models consistently show that aqueous, ethanolic, and hydro-alcoholic extracts of *O. sanctum* leaves significantly lower fasting and post-prandial blood glucose levels.
- **Clinical Evidence:** Human trials, including randomized placebo-controlled crossover studies, found that consuming *O. sanctum* leaf powder (e.g., 2 grams daily) can lead to significant reductions in blood glucose, cholesterol, triglycerides, and improved HbA1c levels in patients with type 2 diabetes.
- **Lipid Profile Improvement:** The extracts also demonstrate beneficial effects on associated metabolic parameters, such as reducing LDL ("bad") cholesterol and triglycerides while increasing HDL ("good") cholesterol, thus mitigating cardiovascular risks associated with diabetes.

Mechanisms of Action:

The antidiabetic effect is multifaceted:

- **Insulin Secretion:** Extracts have been shown to stimulate insulin secretion from pancreatic beta-cells.
- **Enzyme Inhibition:** Bioactive compounds inhibit carbohydrate-hydrolyzing enzymes like alpha-glucosidase, which slows down glucose absorption from the intestine.
- **Antioxidant Activity:** Diabetes is often associated with elevated oxidative stress. *O. sanctum*'s high content of phenolic compounds and flavonoids provides significant antioxidant activity, which protects pancreatic cells and other organs from damage.
- **Anti-inflammatory Effects:** The plant exhibits potent anti-inflammatory properties that help manage the chronic inflammation linked to metabolic syndrome and diabetes complications.

Bioactive Compounds:

The therapeutic benefits are attributed to specific compounds:

- **Eugenol and Ursolic Acid:** These are the primary compounds widely cited for their role in glucose metabolism and insulin modulation.
- **Polyphenols/Flavonoids:** Rosmarinic acid, apigenin, cirsimaritin, orientin, and vicenin also play significant roles.
- **Novel Triterpenoids:** Specific tetracyclic triterpenoids have been isolated via bioactivity-guided fractionation and identified as highly potent antihyperglycemic agents.

Gaps and Future Research Directions

Current literature emphasizes the need for:

- More rigorous, large-scale, long-term human clinical trials to standardize dosage and confirm safety for regulatory approval.
- Further research to fully elucidate the exact molecular pathways and identify all responsible phytochemicals.
- Development of novel delivery systems, such as nanoencapsulation, to improve the bioavailability and efficacy of the active compounds.

Rationale for Research

The rationale for this research is based on addressing the limitations of existing antidiabetic therapies and validating the traditional potential of *O. sanctum*:

- **Need for Safer Alternatives:** Conventional synthetic antidiabetic drugs often cause side effects such as hypoglycemia, weight gain, and liver/kidney issues. Natural compounds from *O. sanctum* are perceived to have fewer adverse effects and are safer for long-term consumption, as suggested by their extensive traditional use.
- **Scientific Validation of Traditional Claims:** The research provides scientific evidence to verify and validate the traditional use of *O. sanctum* as an antidiabetic agent, moving beyond anecdotal evidence to evidence-based medicine.
- **Potential for Novel Drug Development:** The isolation and characterization of potent, specific compounds, such as the unique tetracyclic triterpenoid, could lead to the development of novel single-compound drugs with defined efficacy and predictable pharmacokinetics, offering new avenues for diabetes treatment.
- **Understanding Holistic Mechanisms:** Diabetes is a complex condition involving oxidative stress and inflammation. *O. sanctum* offers a holistic approach by addressing these underlying complications in addition to blood sugar management. Characterizing individual compounds allows researchers to understand how they work synergistically or individually to mitigate various aspects of the disease.
- **Standardization and Quality Control:** Isolating and characterizing the active compounds is essential for standardizing extracts and developing high-quality nutraceutical formulations that ensure consistent potency and efficacy across different batches and products.

3. Objectives of the Study

The objectives of a study focused on the isolation and characterization of bioactive compounds from

Ocimum sanctum leaves for antidiabetic use are designed to move from basic compound identification to understanding their therapeutic potential.

- To isolate, purify, and characterize the specific bioactive phytochemicals from *Ocimum sanctum* leaves that exhibit significant antidiabetic activity, and to elucidate their potential mechanisms of action.

1. Extraction and Isolation:

- To prepare and screen various crude extracts (e.g., aqueous, hydroalcoholic, ethanolic) from *Ocimum sanctum* leaves to determine the most potent fraction for further study using bioactivity-guided fractionation methods.
- To systematically isolate and purify individual compounds from the most active fraction using advanced chromatographic techniques (e.g., column chromatography, HPLC, TLC).

2. Chemical Characterization:

- To determine the precise chemical structure of the isolated potent compounds using comprehensive spectroscopic methods, including UV-Visible spectroscopy, Fourier-Transform Infrared (FTIR) spectroscopy, Mass Spectrometry (MS), and Nuclear Magnetic Resonance (NMR) spectroscopy.

3. Evaluation of Antidiabetic Activity:

- To evaluate the *in vitro* antidiabetic potential of the isolated compounds by assessing their ability to inhibit key carbohydrate-hydrolyzing enzymes, such as -glucosidase.
- To assess the *in vivo* efficacy of the pure compounds in established animal models of diabetes (e.g., alloxan or streptozotocin-induced diabetic rats), measuring parameters such as fasting blood glucose levels, insulin secretion, and glycated hemoglobin (

4. Elucidation of Mechanisms of Action:

- To investigate the cellular and molecular mechanisms by which the isolated compounds exert their hypoglycemic effects, such as stimulating insulin secretion from pancreatic beta-cells, enhancing peripheral glucose uptake, or increasing antioxidant defense mechanisms.

5. Safety Assessment (Optional but Recommended):

- To perform preliminary toxicity assessments of the most active compounds to ensure their safety profile for potential therapeutic application.

Key Outcomes

- **Identification of novel compounds:** Researchers successfully isolated and characterized specific compounds, such as a unique tetracyclic triterpenoid, which were found to be highly effective in reducing blood glucose levels in diabetic models.
- **Insulin Secretion Stimulation:** The aqueous, butanol, and ethyl acetate fractions were shown to stimulate insulin secretion from pancreatic beta-cells in a glucose-dependent manner, indicating an action similar to some conventional antidiabetic drugs.
- **Improved Glucose Utilization:** *O. sanctum* extracts were found to enhance glucose utilization by peripheral tissues and increase glycogen synthesis in the liver, effectively removing excess glucose from the bloodstream.
- **Enzyme Inhibition:** Ethanolic extracts demonstrated significant inhibitory effects on carbohydrate-hydrolyzing enzymes like alpha-amylase, which helps to slow down the digestion and absorption of carbohydrates, thereby managing postprandial glucose spikes.
- **Antioxidant and Anti-inflammatory Effects:** A major outcome is the confirmation of strong antioxidant activity through compounds like orientin, vicenin, and rosmarinic acid. These help mitigate the oxidative stress and inflammation associated with diabetic complications, offering a holistic benefit beyond just glycemic control.

- **Favorable Lipid Profile Changes:** Studies showed that the extracts not only lowered blood glucose but also improved lipid profiles by reducing total cholesterol and triglycerides and increasing beneficial HDL cholesterol, thus reducing cardiovascular risks associated with diabetes.
- **Safety Profile:** The ethanol extract of *O. sanctum* was generally well-tolerated in animal studies, with no significant toxicity observed at effective doses, suggesting a favorable safety margin for potential therapeutic use.
- Summary of Antidiabetic Bioactive Compounds and Mechanisms

Bioactive Compound Class	**Specific Compound**	**Key Antidiabetic Mechanism(s)**	**Research Outcome**
Triterpenoid	Tetracyclic triterpenoid	Stimulates insulin secretion from pancreatic ***β*** *β* cells and enhances glucose utilization.	Significant reduction in fasting blood glucose (FBG) and improved glucose tolerance in diabetic rats.
Phenolic Compound	Eugenol	Inhibits alpha-glucosidase enzyme activity, slowing carbohydrate digestion.	Lowered postprandial blood glucose levels; major constituent responsible for hypoglycemic effects.
Flavonoids	Orientin, Vicenin, Apigenin	Potent antioxidant activity; protects pancreatic beta-cells from oxidative stress and improves insulin sensitivity.	Reduced lipid peroxidation (MDA levels) and increased activity of antioxidant enzymes (SOD, CAT, GPx).
Phenolic Acid	Rosmarinic Acid	High free radical scavenging ability and proton-donating activity.	Contributes to the overall antioxidant capacity of the extract, reducing long-term diabetic complications.
Sterol/Fatty Acid	*β* *β* sitosterol / Linoleic acid	Improves glucose uptake in cells and regulates lipid metabolism.	Improved lipid profiles (reduced cholesterol/triglycerides) and enhanced glucose uptake pathways.

Future Scope and Recommendations

The isolation and characterization of potent bioactive compounds from *Ocimum sanctum* leaves provide a strong foundation for future research and therapeutic development. Addressing the existing research gaps will be essential for translating these findings into clinical practice.

Future Scope

1. **Clinical Trials:** The most crucial next step is the transition to human clinical trials. Future research should focus on randomized, controlled human studies to evaluate the efficacy, optimal dosage, and long-term safety of the standardized *O. sanctum* extracts or specific isolated compounds (e.g., the tetracyclic triterpenoid) in patients with Type 1 and Type 2 diabetes.

2. **Pharmacokinetic Studies:** Comprehensive ADME (Absorption, Distribution, Metabolism, and Excretion) studies are needed to understand how the isolated compounds behave in the human body. This will help determine bioavailability, appropriate dosage forms (e.g., tablets, capsules), and potential drug-drug interactions.
3. **Molecular Mechanism Elucidation:** While mechanisms have been suggested, future studies should use advanced molecular biology techniques (e.g., gene expression analysis, proteomics) to precisely map the pathways targeted by the active compounds, perhaps comparing their mechanisms to conventional drugs.
4. **Synergistic Formulations:** Investigating the synergistic effects of combining *O. sanctum* extracts with existing conventional antidiabetic medications (like metformin or sulfonylureas) could lead to optimized combination therapies that potentially reduce the required dosage of synthetic drugs, minimizing their side effects.
5. **Targeted Delivery Systems:** Development of advanced drug delivery systems, such as nanoparticles or liposomal encapsulations, could enhance the bioavailability and targeted delivery of the active compounds to the pancreas or liver, improving efficacy at lower doses.

Recommendations

- **Standardization of Extracts:** Regulatory bodies should encourage the development of standardized *O. sanctum* extracts with clearly defined concentrations of key active markers (e.g., eugenol, ursolic acid, orientin). This ensures consistency and reproducibility of therapeutic effects across different commercial products.
- **Safety and Toxicology Focus:** Although traditional use suggests safety, rigorous preclinical toxicological studies (chronic toxicity) must be performed on purified compounds before human use is widespread.
- **Mechanistic Research Emphasis:** Researchers should prioritize studies that definitively prove causality between a specific compound and a specific antidiabetic effect (e.g., direct inhibition of an enzyme versus indirect antioxidant effects), rather than general extract efficacy.
- **Regulatory Frameworks:** Development of clear regulatory guidelines for herbal-derived medicines is necessary to streamline the approval process for *O. sanctum*-based products as official pharmaceutical treatments or high-quality nutraceuticals.

References: -

1. annan, J. M. A., Marenah, L., Ali, L., Rokeya, B., Flatt, P. R., & Abdel-Wahab, Y. H. A. (2006). *Journal of Endocrinology*, *189*(1), 127–136. (For details, see Ijbcp.com)
2. Patil, P. A., Kulkarni, D. K., & Rather, P. M. (2011). *Asian Pacific Journal of Tropical Medicine*, *4*(4), 278–282.
3. Rajan, S. S., & Sampath, G. K. (2024).
4. Reddy, S. S., Karuna, R., Baskar, R., & Saralakumari, D. (2008). *Hormone and Metabolic Research*, *40*(1), 44–49. (For details, see Ijbcp.com)
5. Suanarunsawat, T., Ayutthaya, W. D., Thirawarapan, S., & Poungshompoo, S. (2014). *Food and Nutrition Sciences*, *5*(8), 801-811. (For details, see Ijbcp.com)
6. Thakur, K. (2009). Ijbcp.com
7. Vats, V., Yadav, S. P., Biswas, N. R., & Grover, J. K. (2004). *Journal of Ethnopharmacology*, *90*(1), 155–160.